Burnett Patrick sold $25K of ARQT
Burnett Patrick (See Remarks) sold 955 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $26.12 on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides transparency on insider activity but does not include new guidance, trial results, regulatory actions, or deal terms.
Market read
A small, scheduled insider sale is unlikely to drive fundamentals, but it can marginally influence sentiment around ARQT.
What to watch
Traders may overreact to insider sales; the key is whether there is a pattern of repeated sales outside scheduled plans, which is not evidenced here.
Background
The article is an SEC Form 4 insider transaction report for Arcutis Biotherapeutics, Inc.
Ticker impact
Arcutis Biotherapeutics insider Burnett Patrick sold 955 shares in an open-market transaction on Aug 3 under a 10b5-1 plan.
Likely limited, short-lived impact unless follow-on selling appears.
The filing is a Form 4 open-market sale with a pre-arranged 10b5-1 plan; no new company-specific operational or financial information is provided.
Market effects
Minimal; insider sale does not signal sector-wide change.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect liquidity needs rather than bearish expectations.
Key entities
- issuerArcutis Biotherapeutics, Inc.
US-listed biotherapeutics company subject of the Form 4 insider sale disclosure.
- insiderBurnett Patrick
Officer who sold 955 shares on Aug 3 at $26.1168/share under a 10b5-1 plan.
